NEW YORK (GenomeWeb News) – German molecular diagnostics company Curetis said today it anticipates filing a 510(k) submission with the US Food and Drug Administration for its Unyvero System in 2014.

In preparation of a submission, the company has begun a clinical trial for the system and its lower respiratory tract (LRT) application. Curetis expects the trial to last between 12 and 15 months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

In Genome Biology this week: miRNAs linked to diffuse large B-cell lymphoma outcomes, database of bird genomes, and more.